Development fo a novel treatment for asthma: the identification of lead small molecule antagonists of the IL-13/IL-13 re

哮喘新疗法的开发：IL-13/IL-13 re 的主要小分子拮抗剂的鉴定

• 批准号: nhmrc : 305538
• 负责人: A/Pr Ian Street
• 金额: $ 6.65万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-fo-novel-13il-13/76498
• 关键词: Development; fo; novel; treatment; asthma

In developed countries Asthma ranks among the most common chronic illnesses. Over two million Australians now have this condition and the cost to our community is estimated to be in excess of $720 million per annum. In 1996 researchers at The Walter and Eliza Hall Institute discovered a new member of the cytokine receptor family, IL-13Ra1, which further research has strongly implicated in the pathology of this disease. The main goal of the proposed research is to discover small molecule antagonists of IL-13Ra1 and to identify those suitable for development as novel asthma therapeutics.

在发达国家，哮喘是最常见的慢性疾病之一。现在超过 200 万澳大利亚人患有这种疾病，我们社区每年的损失估计超过 7.2 亿澳元。 1996 年，沃尔特和伊丽莎·霍尔研究所的研究人员发现了细胞因子受体家族的新成员 IL-13Ra1，进一步的研究表明该成员与这种疾病的病理学密切相关。该研究的主要目标是发现 IL-13Ra1 的小分子拮抗剂，并确定那些适合开发为新型哮喘治疗药物的拮抗剂。